Dirk Van Hyfte MD, PhD, Co-Founder and
Head of Innovation of BioStrand, to present findings live next week
at the HIMSS24 conference in Orlando, Florida
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA), an artificial intelligence-driven biotherapeutic
research and technology company, today announced the development of
a Foundation AI Model that represents a significant advancement in
life sciences research and development. The Company’s model
uniquely combines the strengths of Large Language Models (LLMs)
through an advanced stacking technique with BioStrand's patented
HYFT Technology. The HYFT's ability to pinpoint unique
'fingerprints' in biological sequences enables the stacked LLMs to
apply their vast knowledge base with greater specificity, leading
to more accurate predictions and insights. This integration marks a
pivotal moment in the utilization of artificial intelligence for
complex biological data analysis and drug discovery.
Unveiling the Intricacies of HYFT Technology
Central to the success of BioStrand's Foundation AI Model is its
utilization of its patented HYFT technology, a sophisticated
framework designed to identify and leverage universal fingerprint™
patterns across the biosphere. These fingerprints act as critical
anchor points, encompassing detailed information layers that bridge
sequence data to structural data, functional information,
bibliographic insights, and beyond, serving as the great connector
between disparate realms of knowledge. BioStrand’s platform core is
built upon a comprehensive and continuously expanding knowledge
graph, mapping 25 billion relationships across 660 million data
objects, and linking sequence, structural, and functional data from
the entire biosphere to written text such as scientific literature,
providing a holistic understanding of the relationships between
genes, proteins, and biological pathways.
The seamless integration of HYFTs with stacked LLMs enables the
BioStrand AI model to decode the complex language of proteins,
unlocking insights crucial for antibody drug development and
precision medicine.
Large Language Models (LLM), originally developed for Natural
Language Processing (NLP), can also be applied on “the language of
proteins” enabling insights into tasks including, but not limited
to, protein structure prediction, antibody binding optimization,
and protein mutagenesis.
To understand ‘the language of proteins’, it is essential to
detect meaningful words and word boundaries. This is where the
HYFTs serve as critical enablers. By harnessing HYFT's
sophisticated computational capabilities, the previously abstract
notion of identifying functional units or "words" in protein
sequences is made tangible, allowing for precise mapping and
analysis.
The Advanced Foundation AI model employs a distinctive approach
known as "LLM stacking" to intelligently combine different LLMs,
with the HYFTs linked to specific features found in various LLMs.
Using a natural language analogy, this would mean one is able to
distinguish the meaning of ‘apple’ based specifically on the
context of the word, in other words, is the word “apple” referring
to a type of fruit versus ‘Apple’, Silicon Valley pioneer. In a
life sciences context, these features, for example, could include
identification of critical amino acid residues involved in protein
binding or detecting sequence variations associated with disease
susceptibility. The sequence diversity harnessed by the HYFTs was
discovered during the clustering of Next Generation Sequencing data
sourced from IPA’s pipeline subsidiary, Talem Therapeutics,
utilizing the HYFT network combined with LLM stacking. Through the
incorporation of various features provided by LLM stacking in this
study, it was possible to differentiate between binding and
non-binding antibodies, even when they shared similar HYFT
patterns.
Pioneering a New Frontier in Life Sciences
The concept of "word boundaries" within protein languages offers
a groundbreaking approach to unlocking the complexities of protein
structure and function, filling a void in the knowledge base of
researchers and drug developers alike. By enabling precise
identification and manipulation of functional units within
proteins, this innovative methodology paves the way for
advancements in drug discovery, protein-based therapeutics, and
synthetic biology. It promises not only to accelerate the
development of targeted treatments with higher efficacy and lower
side effects but also to revolutionize protein engineering and
design. This approach, leveraging cutting-edge computational models
and analysis techniques, stands to significantly reduce research
and development timelines and costs .
Advancing Drug Discovery and Precision Medicine - LENSai
™ Integrated Intelligence Technology™
This methodology revolutionizes biotechnology and pharmaceutical
research by providing a robust framework for drug discovery,
protein engineering, and the development of protein-based
therapeutics. The HYFT technology’s application of "word
boundaries" is particularly compelling, as it aims to significantly
accelerate research and development processes. Through the
facilitation of targeted treatments and the innovation of novel
therapies, the HYFT technology offers a reduction in development
timelines and costs .
By providing a comprehensive understanding of the complex
relationships between genes, proteins, and biological pathways, the
model paves the way for the development of targeted therapies and
personalized treatment strategies.
Reaffirming BioStrand's Leadership in Biotech
Innovation
"The development of our Foundation AI Model, powered by our
unique 'LLM stacking' approach and patented HYFT technology, marks
a significant milestone in the field of biotechnological research,"
stated Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of
BioStrand. "This innovation not only expands the boundaries of
current biotech research, but also establishes a new standard for
the application of AI in solving complex biological
challenges."
“As the global community recognizes the transformative potential
of artificial intelligence in the life sciences,” Dr. Hyfte
continued, “I am confident that BioStrand's Foundation AI Model
will stand at the forefront of innovation and the future of
AI-driven solutions in biology and drug discovery.”
A Future of Collaborative Discovery
In alignment with our mission to foster collaboration and
innovation within the life sciences community, we are excited to
announce that IPA's CEO, Dr. Jennifer Bath, will participate in the
H.C. Wainwright 1st Annual Artificial Intelligence Based Drug
Discovery & Development Virtual Conference today March 7th,
2024. This participation underscores our commitment to leading the
conversation on the future of AI-driven solutions in biology and
medicine.
Additionally, we are thrilled to announce the participation of
Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of
BioStrand, alongside our esteemed technology partner, InterSystems,
at this year's HIMSS®24 conference in Orlando, Florida. Together,
we will be showcasing our latest advancements in the field of
healthcare technology through InterSystems’s Innovator Introduction
program.
Our presentation will focus on introducing our groundbreaking
Universal Foundation AI Model for Multiscale Biological Data
Integration.
We invite you to join us for our lightning pitch session, where
we will delve into the capabilities and potential impact of our
Universal Foundation AI Model. Also, we welcome you to engage in
fruitful conversations at InterSystem's booth, #1361 at the HIMSS
conference, March 12th-14th, 2024.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modelling and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
expected outcome on the market, the life sciences, drug discovery
and development, integration and / or success of LENSai, LLMs, RAG,
or HYFT technologies, including their benefits, and statements
relating to IPA’s expected increased revenue streams and financial
growth. In respect of the forward-looking information contained
herein, IPA has provided such statements and information in
reliance on certain assumptions that management believed to be
reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the integration of IPA’s LENSai platform
with its HYFT technology may not have the expected results, risks
that the expected healthcare benefits including lowering
development timeliness, and costs and that development of targeted
treatments with higher efficacy and lower side effects will not be
achieved, risks that the benefits to drug discovery, protein-based
therapeutics, and synthetic biology won't be achieved, in addition
actual results could differ materially from those currently
anticipated due to a number of factors and risks, as discussed in
the Company’s Annual Information Form dated July 10, 2023 (which
may be viewed on the Company’s profile at www.sedar.com), and the
Company’s Form 40-F, dated July 10, 2023 (which may be viewed on
the Company’s profile at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. Accordingly, readers should not
place undue reliance on forward-looking information contained in
this news release. The forward-looking statements contained in this
news release are made as of the date of this release and,
accordingly, are subject to change after such date. The Company
does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240307470977/en/
investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 4 2024 まで 5 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 5 2023 まで 5 2024